Related Experiment Videos
Cutaneous lupus erythematosus: a review
Purvisha Patel1, Victoria Werth
1University of Virginia, Charlottesville, VA, USA.
Dermatologic Clinics
|August 13, 2002
Summary
This review updates knowledge on cutaneous lupus erythematosus (CLE), a skin condition that can occur with or without systemic lupus erythematosus (SLE). Certain symptoms in CLE patients may indicate a higher risk of developing SLE.
Area of Science:
- Dermatology
- Immunology
- Internal Medicine
Background:
- Cutaneous lupus erythematosus (CLE) encompasses various skin manifestations, with or without systemic lupus erythematosus (SLE).
- Skin involvement is common in SLE, affecting up to 70% of patients.
- Prevalence of SLE is estimated at 17-48 per 100,000 worldwide.
Purpose of the Study:
- To review and update current information on the pathogenesis, clinical presentation, diagnosis, and treatment of cutaneous lupus erythematosus.
- To highlight the relationship between CLE and SLE, including risk factors for transition.
Main Methods:
- Literature review and synthesis of existing data on cutaneous lupus erythematosus.
- Analysis of clinical presentations and diagnostic criteria.
- Discussion of treatment strategies and prognostic indicators.
Main Results:
- CLE is classified into chronic, subacute, and acute forms.
- Common mucocutaneous manifestations in SLE include malar rash (40%), alopecia (24%), and oral ulcers (19%).
- High ANA titers (> 1:320) and arthralgias are potential risk factors for progression from CLE to SLE.
Conclusions:
- Close monitoring of CLE patients with risk factors like high ANA titers and arthralgias is crucial.
- Early identification and management of CLE can aid in predicting and potentially mitigating SLE development.